In August of 2006, Brazilian lawmakers decriminalized the use of cannabis and replaced prosecution with a warning or potential community service. By 2014, CBD-based medicines were being imported for people who suffer from a variety of conditions. In January, Brazil’s healthcare regulator Anvisa issued the first license for the sale of a cannabis-based medicine in the country.
By the end of this year, Anvisa intends to enact regulations for domestic medical marijuana cultivation for the purposes of scientific research and extract production.
Marijuana.com spoke with Carlos Estênio Brasilino, the Chief Communications Officer of Anvisa to get a sense of what the future of cannabis in Brazil will look like.
(Marijuana.com) What forms of medical marijuana are currently available in Brazil?
Anvisa has authorized the import of cannabidiol-based products since 2014, for the treatment of syndromes that cause multiple episodes of convulsion, among other indications.
Anvisa has recently approved the registration of Mevatyl®, a THC and cannabidiol-based drug, indicated for the symptomatic treatment of moderate to severe spasticity related to multiple sclerosis.